Axitinib API CAS 886230-75-7

Overview: Axitinib is a multi-targeted small molecule inhibitor, the main targets are VEGFR, Kit, PDGFR, RET. The currently approved indication for the market is the second-line treatment of advanced renal cancer, which means that axitinib can be selected for advanced renal cancer after the failure of the chemicalbook treatment of Sutent. In addition to renal cancer, this drug has also been tried by patients for liver cancer, sarcoma, neuroendocrine tumors and other solid tumors that are relatively sensitive to anti-angiogenic drugs and have a rich tumor blood supply, and has certain curative effects. Introduction:Axitinib is a white powder with a melting point of 218.4°C, slightly soluble in polyethylene glycol 400, slightly soluble in methanol or ethanol, very slightly soluble in acetonitrile, and almost insoluble in water. The solubility in pHChemicalbook1.2 hydrochloric acid solution at 20°C is 0.8 mg/ml, and the solubility in pH6.8 phosphate buffer solution is 0.2 μg/ml, whic…

A Picture Interactive Platform For Global Opportunities

Copyrights © 2022 All Rights.Reserved .